Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Arid1a promotes tumor initiation but restrains progression and metastasis in liver cancer [ChIP-Seq]

ABSTRACT: ARID1A is hypothesized to be one of the most common tumor suppressors in human cancer. However, the functional consequences of ARID1A gain and loss are not clear. We report that mice with complete liver-specific Arid1a deficiency were resistant to MYC induced liver carcinogenesis, indicating a requirement during tumor initiation. Mechanistically, Arid1a loss constrained tumor formation by reducing Cytochrome P450 expression, which in turn mitigated oxidative stress. We also examined the heterozygous state and found it potentiated metastasis formation and heterozygous has similar gene accessibility pattern with homozygous compared to WT.

ORGANISM(S): Mus musculus

PROVIDER: GSE102607 | GEO | 2017/12/13

SECONDARY ACCESSION(S): PRJNA398201

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Arid1a promotes tumor initiation but restrains progression and metastasis in liver cancer [RNA-seq]

Project description:ARID1A is hypothesized to be one of the most common tumor suppressors in human cancer. However, the functional consequences of ARID1A gain and loss are not clear. We report that mice with complete liver-specific Arid1a deficiency were resistant to MYC induced liver carcinogenesis, indicating a requirement during tumor initiation. Mechanistically, Arid1a loss constrained tumor formation by reducing Cytochrome P450 expression, which in turn mitigated oxidative stress. We also examined the heterozygous state and found it potentiated metastasis formation and heterozygous has similar gene expression pattern with homozygous compared to WT.

2017-12-13 | GSE95537 | GEO

Arid1a promotes tumor initiation but restrains progression and metastasis in liver cancer [ATAC-seq]

2017-12-13 | GSE95530 | GEO

SWI/SNF component ARID1A restrains pancreatic neoplasia formation [RNA-seq]

Project description:ARID1A restrains the formation of PanIN, pancreas ductal adenocarcinoma, and intraductal mucinous neoplasms

2018-09-12 | GSE119779 | GEO

SWI/SNF component ARID1A restrains pancreatic neoplasia formation [ChIP-seq]

Project description:ARID1A restrains the formation of PanIN, pancreas ductal adenocarcinoma, and intraductal mucinous neoplasms

2018-09-12 | GSE119858 | GEO

SWI/SNF component ARID1A restrains pancreatic neoplasia formation

Project description:SWI/SNF component ARID1A restrains pancreatic neoplasia formation

| PRJNA490490 | ENA

Arid1a promotes tumor initiation but restrains progression and metastasis in liver cancer

Project description:Arid1a promotes tumor initiation but restrains progression and metastasis in liver cancer

| PRJNA377344 | ENA

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy [scRNA-Seq]

Project description:Gastric cancer (GC) is one of the most common deadly cancers in the world. Although patient genomic data have identified ARID1A, a key chromatin remodeling complex subunit, as the second most frequently mutated gene after TP53, its in vivo role and relationship to TP53 in gastric tumorigenesis remains unclear. Establishing a novel mouse model that reflects the ARID1A heterozygous mutations found in the majority of human GC cases, we demonstrated that Arid1a heterozygosity facilitates tumor progression through a global loss of enhancers and subsequent suppression of the p53 and apoptosis pathways. Moreover, our mouse genetic and single cell analyses demonstrated that the homozygous deletion of Arid1a confers a competitive disadvantage through the activation of the p53 pathway, highlighting its distinct dosage dependent roles. Utilizing this unique vulnerability of Arid1a mutated GC cells, our combinatorial treatment with an epigenetic inhibitor and a p53 agonist selectively inhibited Arid1a heterozygous tumor growth, providing a novel therapeutic option for GC.

2021-03-16 | GSE144387 | GEO

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy [RNA-Seq]

2021-03-16 | GSE144386 | GEO

Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy [ChIP-Seq]

2021-03-16 | GSE144385 | GEO

SWI/SNF component ARID1A restrains pancreatic neoplasia formation [RNA-seq]

Project description:SWI/SNF component ARID1A restrains pancreatic neoplasia formation [RNA-seq]

| PRJNA490279 | ENA